Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 17, 2021 7:19pm
177 Views
Post# 32591702

RE:RE:RE:RE:RE:RE:RE:Warrants

RE:RE:RE:RE:RE:RE:RE:WarrantsThe warrents:
A few years back, I was quite certian the warrents were 1 for one on shares.
Called Micahel Moore of then ONC I.R. he got back to me pronto.

The ONC warrents were not adjusted during the R/S and as such you need 9.5 warrents to buy one share. That-said: 
The value is still there if the Sp gets above the strike price.
Just not as lucrative as you think.
and the warrents sold on the TSX are not the same warrents on the nas. Different series etc.

Moving on, because IMHO the warrents are a red-herring right now.

Oncolytics biotech is at the cross roads of a great opportunity.
Mangenent has been dead silent months. 

Meaning:
They have nothing to say or are in a media black-out due to a deal negotiations.

The recent trading voluem: Notable the cross 2 weeks ago at $3million, indoates institutions are on the buy.
The rating of $15 Ps indicates institutions are following.

One good N.R. and the price will move & stay above $10Ps.
hang in all, and have a safe & healthy week.



<< Previous
Bullboard Posts
Next >>